Latest News

Is Fluor stock your best bet to profit from the nuclear renaissance? It certainly looks cheap enough.

This mining company is poised to become the U.S.'s go-to supplier for rare earth magnets.

Both of these stocks have underperformed in 2025. But they could crush the market in 2026 and beyond.

Private credit, like private equity, encompasses a vast array of different assets with equally vast risks.

Some 0% intro APR cards offer up to 21 months of no interest. Here's how paying just $285 a month can knock out $6,000 in credit card debt.

Opendoor has outperformed the S&P 500 recently, but this could soon change in a big way.

The Shiller CAPE ratio is flashing warning signs.

XRP spot ETFs saw $643.92 million in net inflows in their debut month, reaching $676.49 million in total assets.

DRDGOLD (DRD) aligns with Peter Lynch's GARP strategy, showing strong EPS growth, minimal debt, high profitability, and an attractive PEG ratio under 1.0.

The pharma stock yields more than 4x the S&P 500 average.

Lemonade (LMND) stock meets Mark Minervini's strict Trend Template with strong technicals and accelerating fundamental growth in revenue and earnings.

Since 2023, these stocks have soared between 490% and 2,400%.

Wall Street is bullish on Nvidia's stock.

Nasdaq price prediction based on the technical analysis.

Oracle is one of the biggest names in enterprise software and cloud services. They power databases used by governments, banks, hospitals, airlines, and global corporations.

These funds offer yields that are more than three times the S&P 500 average.

Catalyst Pharmaceuticals offers strong growth, solid profitability, and a debt-free balance sheet, all at an attractive valuation compared to its biotech peers.

AEP stock shows strong technicals and a high-quality breakout setup, trading near 52-week highs with defined entry and stop levels.

Discover the catalysts that could ignite CrowdStrike's next big move and see why analysts believe the stock still has major upside.

Once again, Trump says tariffs can replace the income tax.

The stock has lagged broader equities this year, but patient investors who initiate positions today might be very well rewarded in a decade.

Lucid Group stock is currently high risk, high reward.

Smith & Nephew (SNN) is a value investment in medical devices, with strong profitability, accelerating growth, and attractive valuation metrics.

There are several great deals investors should be taking advantage of.